Ocuphire Pharma Inc Forecast, price target & analysts
Ocuphire Pharma Inc Target price 2026 - Analyst rating & recommendation
Ocuphire Pharma Inc Classifications & Recommendation
Ocuphire Pharma Inc Price Target
| Target Price | $10.20 |
| Price | $4.87 |
| Potential |
109.45%
register free of charge
|
| Number of Estimates | 20 |
|
20 Analysts have issued a price target Ocuphire Pharma Inc 2027 .
The average Ocuphire Pharma Inc target price is $10.20.
This is
109.45%
register free of charge
$16.80
244.97%
register free of charge
$8.08
65.91%
register free of charge
|
|
| A rating was issued by 23 analysts: 22 Analysts recommend Ocuphire Pharma Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Ocuphire Pharma Inc stock has an average upside potential 2027 of
109.45%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 14.20 | 12.42 |
| 29.21% | 12.51% | |
| EBITDA Margin | -256.69% | 168.28% |
| 10.04% | 165.56% | |
| Net Margin | -349.23% | -658.87% |
| 33.29% | 88.67% |
19 Analysts have issued a sales forecast Ocuphire Pharma Inc 2026 . The average Ocuphire Pharma Inc sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an Ocuphire Pharma Inc EBITDA forecast 2026. The average Ocuphire Pharma Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2025 | $-36.5m | 16.23% |
|---|---|---|
| 2026 |
$20.9m
157.36%
unlock
|
|
EBITDA Margin
| 2025 | -256.69% | 10.04% |
|---|---|---|
| 2026 |
168.28%
165.56%
unlock
|
|
20 Ocuphire Pharma Inc Analysts have issued a net profit forecast 2026. The average Ocuphire Pharma Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.80 | -0.99 |
| 62.79% | 23.75% | |
| P/E | negative | |
| EV/Sales | 28.38 |
20 Analysts have issued a Ocuphire Pharma Inc forecast for earnings per share. The average Ocuphire Pharma Inc EPS is
This results in the following potential growth metrics and future valuations:
Ocuphire Pharma Inc...
Current Ocuphire Pharma Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Wedbush |
Locked
➜
Locked
|
Locked | Sep 10 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 09 2026 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Sep 09 2026 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | Sep 09 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | Sep 09 2026 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Aug 07 2026 |
| TD Cowen |
Locked
➜
Locked
|
Locked | Jul 29 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Wedbush:
Locked
➜
Locked
|
Sep 10 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 09 2026 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Sep 09 2026 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Sep 09 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
Sep 09 2026 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Aug 07 2026 |
|
Locked
TD Cowen:
Locked
➜
Locked
|
Jul 29 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
